Ifirmacombi

Hydrochlorothiazide and Irbesartan, the active ingredients in Ifirmacombi, are a thiazide diuretic and an angiotensin II receptor blocker presented as an oral tablet for oral use. They treat hypertension in adult patients by lowering blood pressure through complementary mechanisms.

GNH USA supplies Ifirmacombi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ifirmacombi is indicated for the management of hypertension, a condition characterized by elevated arterial pressure. - Hypertension: reduces systolic and diastolic blood pressure in adults with primary hypertension. - Cardiovascular risk reduction: helps lower the risk of stroke and myocardial infarction associated with uncontrolled blood pressure. - Combination therapy: provides synergistic blood‑pressure control when a diuretic and an ARB are required together.

Ifirmacombi may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects: - Dizziness: feeling light‑headed, especially after standing. - Headache: mild to moderate intensity. - Increased urination: due to the diuretic component. - Electrolyte imbalance: low potassium or sodium levels. - Fatigue: general tiredness. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hyperkalemia: dangerously high potassium levels. - Severe hyponatremia: markedly low sodium concentration. - Acute kidney injury: sudden decline in renal function. - Pancreatitis: inflammation of the pancreas. - Blood dyscrasias: abnormal blood cell counts.

Before initiating Ifirmacombi, clinicians should assess patient history and monitor relevant parameters. - Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Electrolyte assessment: check potassium and sodium regularly. - Renal function evaluation: monitor serum creatinine and eGFR. - Caution in diabetes: watch for changes in glucose control. - Avoid in severe hepatic impairment: limited data support safe use. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ifirmacombi can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Aliskiren: combined renin‑angiotensin blockade may cause renal dysfunction. - Potassium‑sparing diuretics: risk of hyperkalemia. - NSAIDs: may blunt antihypertensive effect and impair renal function. - Lithium: increased lithium toxicity. - ACE inhibitors: additive risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - Other diuretics: may cause excessive hypotension. - Antihypertensives: additive blood‑pressure lowering. - Antacids containing aluminum or magnesium: may reduce absorption of irbesartan. - CYP2C9 inhibitors (e.g., fluconazole): may raise irbesartan levels. - Digoxin: altered potassium may affect digoxin toxicity.